Publication

Article

Pharmaceutical Technology

Pharmaceutical Technology-09-02-2001
Volume25
Issue 9

Replacing the Animal Component in SerumEvaluating Raw Materials for Inclusion in Optimized Hybridoma Media

With the scarcity of CGMP facilities spurring a production crisis, manufacturers need to optimize their processes and formulations for individual hybridoma cell lines and production systems.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Dave A Miller, PhD, Chief Scientific Officer, AustinPx
Dave Miller, PhD, CSO, AustinPx